Dicerna Pharmaceuticals Inc. (DRNA)

15.39
0.51 3.21
NASDAQ : Health Technology
Prev Close 15.90
Open 15.87
Day Low/High 15.27 / 16.06
52 Wk Low/High 9.31 / 17.98
Volume 474.86K
Avg Volume 406.80K
Exchange NASDAQ
Shares Outstanding 68.32M
Market Cap 1.08B
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant...

Dicerna™ To Present At The Jefferies 2019 Healthcare Conference

Dicerna™ To Present At The Jefferies 2019 Healthcare Conference

Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M.

First Week Of January 2020 Options Trading For Dicerna Pharmaceuticals (DRNA)

First Week Of January 2020 Options Trading For Dicerna Pharmaceuticals (DRNA)

Investors in Dicerna Pharmaceuticals Inc saw new options begin trading this week, for the January 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Dicerna Announces Dosing Of First Patient In Phase 1 Clinical Trial Of DCR-HBVS For The Treatment Of Chronic Hepatitis B Virus

Dicerna Announces Dosing Of First Patient In Phase 1 Clinical Trial Of DCR-HBVS For The Treatment Of Chronic Hepatitis B Virus

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the dosing of the first patient in its Phase 1 clinical trial of DCR-HBVS,...

Dicerna Pharmaceuticals Becomes Oversold (DRNA)

Dicerna Pharmaceuticals Becomes Oversold (DRNA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Dicerna™ Reports First Quarter 2019 Financial And Operating Results And Provides Corporate Update

Dicerna™ Reports First Quarter 2019 Financial And Operating Results And Provides Corporate Update

Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the first quarter ended March 31, 2019.

Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant...

Dicerna™ To Report First Quarter 2019 Financial Results And Host Conference Call On May 9, 2019

Dicerna™ To Report First Quarter 2019 Financial Results And Host Conference Call On May 9, 2019

Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2019 financial results...

Dicerna™ Submits Updated IND Application For DCR-PHXC For Treatment Of Primary Hyperoxaluria (PH) For The PHYOX™2 Pivotal Trial

Dicerna™ Submits Updated IND Application For DCR-PHXC For Treatment Of Primary Hyperoxaluria (PH) For The PHYOX™2 Pivotal Trial

Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the submission of an updated investigational new drug (IND) application to...

Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant...

Dicerna™ To Present At The H.C. Wainwright Global Life Sciences Conference

Dicerna™ To Present At The H.C. Wainwright Global Life Sciences Conference

Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M.

Interesting DRNA Put And Call Options For May 17th

Interesting DRNA Put And Call Options For May 17th

Investors in Dicerna Pharmaceuticals Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DRNA options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

Dicerna™ Announces The Presentation Of Updated Data Demonstrating Utility Of Its Lead Compound DCR-PHXC In Treating Primary Hyperoxaluria Type 1 (PH1) And Type 2 (PH2)

Dicerna™ Announces The Presentation Of Updated Data Demonstrating Utility Of Its Lead Compound DCR-PHXC In Treating Primary Hyperoxaluria Type 1 (PH1) And Type 2 (PH2)

Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA), (the "Company" or "Dicerna") a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the presentation of updated data from its ongoing PHYOX™1 Phase 1...

Dicerna™ Reports Fourth Quarter And Year Ended December 31, 2018 Financial Results And Provides Corporate Update

Dicerna™ Reports Fourth Quarter And Year Ended December 31, 2018 Financial Results And Provides Corporate Update

Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the fourth quarter and year ended December 31, 2018.

Dicerna To Report Fourth Quarter And Year End 2018 Financial Results And Host Conference Call On March 11, 2019

Dicerna To Report Fourth Quarter And Year End 2018 Financial Results And Host Conference Call On March 11, 2019

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its fourth quarter and year end 2018 financial results after market close...

Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA) (the "Company"), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement...

Dicerna Pharmaceuticals To Present At Upcoming Investor Conferences

Dicerna Pharmaceuticals To Present At Upcoming Investor Conferences

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M.

Hardean E. Achneck, M.D., Vice President, Head Of Medical Development (Photo: Business Wire)

Hardean E. Achneck, M.D., Vice President, Head Of Medical Development (Photo: Business Wire)

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the addition of three industry veterans to the Company's management team: This press release features...

Pioneer In Taking RNA Therpeutics Through The Clinic Joins Skyhawk Therapeutics As Chief Medical Officer

Pioneer In Taking RNA Therpeutics Through The Clinic Joins Skyhawk Therapeutics As Chief Medical Officer

Skyhawk signals progression toward the clinical stage with the hire of CMO Dr. Roberto Guerciolini, M.

Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company"), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement...

Dicerna Announces Dosing Of First Volunteer In Phase 1 Clinical Trial Of DCR-HBVS Designed For The Treatment Of Chronic Hepatitis B Virus

Dicerna Announces Dosing Of First Volunteer In Phase 1 Clinical Trial Of DCR-HBVS Designed For The Treatment Of Chronic Hepatitis B Virus

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), (the "Company") a leading developer of RNA interference (RNAi) therapeutics, today announced the dosing of the first human volunteer in its Phase 1 clinical trial of DCR-HBVS, the Company's investigational...

Dicerna Evolves Its Board Of Directors To Support Continued Growth

Dicerna Evolves Its Board Of Directors To Support Continued Growth

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced several changes to its board of directors (BOD), including the elevation of J.

Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), (the "Company"), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that on January 2, 2019, the Compensation Committee of the Company's Board of Directors approved...

First Week Of DRNA February 15th Options Trading

First Week Of DRNA February 15th Options Trading

Investors in Dicerna Pharmaceuticals Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DRNA options chain for the new February 15th contracts and identified one put and one call contract of particular interest.

Boehringer Ingelheim Exercises Option On Second Hepatic Disease Target From Research Collaboration With Dicerna

Boehringer Ingelheim Exercises Option On Second Hepatic Disease Target From Research Collaboration With Dicerna

Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to a second hepatic...

RSI Alert: Dicerna Pharmaceuticals (DRNA) Now Oversold

RSI Alert: Dicerna Pharmaceuticals (DRNA) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Dicerna To Join NASDAQ Biotechnology Index

Dicerna To Join NASDAQ Biotechnology Index

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will be added to the NASDAQ Biotechnology Index (Nasdaq:NBI) as part of the annual...

Dicerna Announces Closing Of Global Licensing And Research Collaboration With Eli Lilly And Company

Dicerna Announces Closing Of Global Licensing And Research Collaboration With Eli Lilly And Company

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the closing of the global licensing and research collaboration between Dicerna and Eli Lilly and Company...

TheStreet Quant Rating: D (Sell)